ACADIA Pharmaceuticals (ACAD) Ratios
ACADIA Pharmaceuticals Ratios
MX:ACAD's free cash flow for Q2 2026 was $124.46M. For the 2026 fiscal year, MX:ACAD's free cash flow was decreased by $-10.30M and operating cash flow was $134.76M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.83 | 2.38 | 2.42 | 4.04 | 6.43 |
| Quick Ratio | 3.71 | 2.32 | 2.28 | 3.99 | 6.35 |
| Cash Ratio | 0.64 | 0.81 | 0.74 | 0.91 | 1.53 |
| Solvency Ratio | 1.20 | 0.53 | -0.18 | -1.14 | -1.03 |
| Operating Cash Flow Ratio | 0.40 | 0.40 | 0.07 | -0.91 | -1.31 |
| Short-Term Operating Cash Flow Coverage | 9.44 | 0.00 | 1.78 | 0.00 | 0.00 |
| Net Current Asset Value | $ 725.31M | $ 483.36M | $ 298.92M | $ 320.54M | $ 458.60M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.04 | 0.08 | 0.11 | 0.09 |
| Debt-to-Equity Ratio | 0.04 | 0.07 | 0.13 | 0.15 | 0.12 |
| Debt-to-Capital Ratio | 0.04 | 0.07 | 0.12 | 0.13 | 0.11 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.27 | 1.62 | 1.73 | 1.47 | 1.29 |
| Debt Service Coverage Ratio | 34.62 | 0.00 | -8.30 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.31 | 0.31 | 0.35 | 0.38 | 0.40 |
| Net Debt to EBITDA | -0.83 | -2.67 | 1.94 | 0.24 | 0.50 |
| Profitability Margins | |||||
| Gross Profit Margin | 91.69% | 91.46% | 93.70% | 98.03% | 96.05% |
| EBIT Margin | 12.96% | 8.80% | -10.10% | -43.23% | -35.20% |
| EBITDA Margin | 14.06% | 10.46% | -9.34% | -42.84% | -34.51% |
| Operating Profit Margin | 9.78% | 24.10% | -10.10% | -43.23% | -35.20% |
| Pretax Profit Margin | 12.96% | 26.94% | -7.03% | -41.27% | -34.60% |
| Net Profit Margin | 36.49% | 23.64% | -8.44% | -41.76% | -34.67% |
| Continuous Operations Profit Margin | 36.49% | 23.64% | -8.44% | -41.76% | -34.67% |
| Net Income Per EBT | 281.49% | 87.75% | 120.08% | 101.19% | 100.21% |
| EBT Per EBIT | 132.53% | 111.82% | 69.55% | 95.46% | 98.29% |
| Return on Assets (ROA) | 25.00% | 19.07% | -8.18% | -36.74% | -23.98% |
| Return on Equity (ROE) | 31.86% | 30.90% | -14.19% | -53.94% | -31.04% |
| Return on Capital Employed (ROCE) | 8.14% | 29.11% | -14.83% | -48.38% | -28.22% |
| Return on Invested Capital (ROIC) | 8.07% | 25.22% | -14.56% | -47.42% | -27.83% |
| Return on Tangible Assets | 26.87% | 21.20% | -8.97% | -36.74% | -23.98% |
| Earnings Yield | 8.64% | 7.45% | -1.19% | -8.39% | -4.48% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.23 | 9.15 | 7.10 | 8.20 | 7.41 |
| Payables Turnover | 8.16 | 5.05 | 2.61 | 0.80 | 2.78 |
| Inventory Turnover | 2.57 | 3.73 | 1.28 | 1.53 | 2.43 |
| Fixed Asset Turnover | 19.53 | 18.86 | 12.86 | 8.40 | 7.30 |
| Asset Turnover | 0.69 | 0.81 | 0.97 | 0.88 | 0.69 |
| Working Capital Turnover Ratio | 1.61 | 2.12 | 1.95 | 1.14 | 0.85 |
| Cash Conversion Cycle | 147.97 | 65.57 | 197.30 | -174.86 | 68.43 |
| Days of Sales Outstanding | 50.49 | 39.90 | 51.43 | 44.51 | 49.26 |
| Days of Inventory Outstanding | 142.19 | 97.89 | 285.89 | 238.26 | 150.28 |
| Days of Payables Outstanding | 44.72 | 72.21 | 140.02 | 457.63 | 131.12 |
| Operating Cycle | 192.68 | 137.79 | 337.31 | 282.77 | 199.55 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.65 | 0.95 | 0.10 | -0.71 | -0.78 |
| Free Cash Flow Per Share | 0.62 | 0.95 | -0.14 | -0.71 | -0.79 |
| Dividend Paid and CapEx Coverage Ratio | 23.42 | 301.57 | 0.42 | 0.00 | -112.00 |
| Capital Expenditure Coverage Ratio | 23.42 | 301.57 | 0.42 | 0.00 | -112.00 |
| Operating Cash Flow Coverage Ratio | 2.10 | 3.03 | 0.29 | -1.84 | -1.95 |
| Operating Cash Flow to Sales Ratio | 0.10 | 0.16 | 0.02 | -0.22 | -0.26 |
| Free Cash Flow Yield | 2.32% | 5.17% | -0.46% | -4.43% | -3.38% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 11.51 | 13.39 | -83.69 | -11.92 | -22.31 |
| Price-to-Sales (P/S) Ratio | 4.22 | 3.17 | 7.06 | 4.98 | 7.74 |
| Price-to-Book (P/B) Ratio | 3.69 | 4.15 | 11.88 | 6.43 | 6.93 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 43.02 | 19.34 | -219.68 | -22.57 | -29.55 |
| Price-to-Operating Cash Flow Ratio | 41.18 | 19.28 | 307.10 | -22.57 | -29.81 |
| Price-to-Earnings Growth (PEG) Ratio | 0.17 | -0.03 | 1.16 | -0.43 | 0.54 |
| Enterprise Value Multiple | 29.19 | 27.69 | -73.68 | -11.38 | -21.92 |
| Enterprise Value | 4.40B | 2.77B | 5.00B | 2.52B | 3.66B |
| EV to EBITDA | 29.19 | 27.69 | -73.68 | -11.38 | -21.92 |
| EV to Sales | 4.10 | 2.90 | 6.88 | 4.87 | 7.57 |
| EV to Free Cash Flow | 41.82 | 17.64 | -214.05 | -22.11 | -28.89 |
| EV to Operating Cash Flow | 40.04 | 17.58 | 299.23 | -22.11 | -29.15 |
| Tangible Book Value Per Share | 6.61 | 3.70 | 2.24 | 2.48 | 3.37 |
| Shareholders’ Equity Per Share | 7.25 | 4.42 | 2.64 | 2.48 | 3.37 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -1.81 | 0.12 | -0.20 | -0.01 | -0.00 |
| Revenue Per Share | 6.33 | 5.78 | 4.43 | 3.20 | 3.02 |
| Net Income Per Share | 2.31 | 1.37 | -0.37 | -1.34 | -1.05 |
| Tax Burden | 2.81 | 0.88 | 1.20 | 1.01 | 1.00 |
| Interest Burden | 1.00 | 3.06 | 0.70 | 0.95 | 0.98 |
| Research & Development to Revenue | 0.31 | 0.32 | 0.48 | 0.70 | 0.49 |
| SG&A to Revenue | 0.51 | 0.51 | 0.54 | 0.00 | 0.82 |
| Stock-Based Compensation to Revenue | 0.00 | 0.07 | 0.09 | 0.13 | 0.13 |
| Income Quality | 0.28 | 0.70 | -0.27 | 0.53 | 0.75 |
Currency in USD
